IL150388A0 - Azaindoles - Google Patents

Azaindoles

Info

Publication number
IL150388A0
IL150388A0 IL15038800A IL15038800A IL150388A0 IL 150388 A0 IL150388 A0 IL 150388A0 IL 15038800 A IL15038800 A IL 15038800A IL 15038800 A IL15038800 A IL 15038800A IL 150388 A0 IL150388 A0 IL 150388A0
Authority
IL
Israel
Prior art keywords
azaindoles
Prior art date
Application number
IL15038800A
Other languages
English (en)
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930698.7A external-priority patent/GB9930698D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of IL150388A0 publication Critical patent/IL150388A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
IL15038800A 1999-12-24 2000-12-27 Azaindoles IL150388A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930698.7A GB9930698D0 (en) 1999-12-24 1999-12-24 Chemical compounds
US21581800P 2000-07-05 2000-07-05
PCT/GB2000/004993 WO2001047922A2 (en) 1999-12-24 2000-12-27 Azaindoles

Publications (1)

Publication Number Publication Date
IL150388A0 true IL150388A0 (en) 2002-12-01

Family

ID=26316153

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15038800A IL150388A0 (en) 1999-12-24 2000-12-27 Azaindoles
IL150388A IL150388A (en) 1999-12-24 2002-06-24 Azaindoles inhibit protein kinase and pharmaceutical preparations containing them
IL193615A IL193615A0 (en) 1999-12-24 2008-08-21 New azaindoles for inhibiting protein kinases and pharmaceutical composition comprising the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL150388A IL150388A (en) 1999-12-24 2002-06-24 Azaindoles inhibit protein kinase and pharmaceutical preparations containing them
IL193615A IL193615A0 (en) 1999-12-24 2008-08-21 New azaindoles for inhibiting protein kinases and pharmaceutical composition comprising the same

Country Status (27)

Country Link
US (2) US6770643B2 (cs)
EP (2) EP1263759B1 (cs)
JP (1) JP5436507B2 (cs)
KR (2) KR100910488B1 (cs)
CN (2) CN100379734C (cs)
AP (2) AP1587A (cs)
AU (1) AU777717B2 (cs)
BG (2) BG66066B1 (cs)
BR (1) BR0017038A (cs)
CA (2) CA2395593C (cs)
CY (1) CY1110951T1 (cs)
CZ (2) CZ301750B6 (cs)
DZ (1) DZ3377A1 (cs)
EA (1) EA005212B1 (cs)
EE (1) EE05180B1 (cs)
HK (1) HK1050191B (cs)
HR (1) HRP20020547B1 (cs)
HU (1) HUP0203895A3 (cs)
IL (3) IL150388A0 (cs)
MA (1) MA26857A1 (cs)
MX (1) MXPA02006338A (cs)
NO (2) NO323766B1 (cs)
NZ (1) NZ519121A (cs)
OA (1) OA12514A (cs)
PL (1) PL209572B1 (cs)
SK (2) SK287882B6 (cs)
WO (1) WO2001047922A2 (cs)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263759B1 (en) 1999-12-24 2010-09-08 Aventis Pharma Limited Azaindoles
PT1363705E (pt) * 2001-02-02 2012-08-17 Bristol Myers Squibb Co Composição e actividade antiviral de derivados de piperazina azaindoleoxoacética substituídos
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US6884889B2 (en) * 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
JP2005534618A (ja) 2002-03-28 2005-11-17 エーザイ株式会社 神経変性疾患用の、ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としての７−アザインドール
ATE457312T1 (de) * 2002-03-28 2010-02-15 Eisai R&D Man Co Ltd Azaindole als hemmstoffe von c-jun n-terminalen kinasen
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
AU2003224257A1 (en) * 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
AU2003259749A1 (en) 2002-08-12 2004-02-25 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
AU2003303678A1 (en) * 2003-01-03 2004-08-10 Genzyme Corporation Urea derivatives and their use as anti-inflammatory agents
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
US7432375B2 (en) * 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
UA88767C2 (uk) 2003-07-17 2009-11-25 Плексікон, Інк. Ppar активні сполуки
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
NZ549079A (en) * 2004-02-20 2010-08-27 Boehringer Ingelheim Int Viral polymerase inhibitors
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006066913A2 (en) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
JP2008521768A (ja) * 2004-12-23 2008-06-26 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
ATE540948T1 (de) 2005-05-20 2012-01-15 Vertex Pharma Pyrrolopyridine als proteinkinasehemmer
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
JP5015154B2 (ja) * 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1963320A1 (en) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
ES2612196T3 (es) * 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
SI1962830T1 (sl) * 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
CA2635899A1 (en) * 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
WO2008014249A2 (en) * 2006-07-24 2008-01-31 Sanofi-Aventis Improved preparations of 2 -substituted pyrrolo [2, 3-b] pyrazine ( 4, 7 -diazaindole ) compounds
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
EP2121692B1 (en) * 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX342814B (es) 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
CN101910152B (zh) * 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
ATE522534T1 (de) * 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
DK2250172T3 (da) 2008-02-25 2012-01-16 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitorer
CA2713710A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
WO2009106445A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
BRPI0907928A2 (pt) 2008-02-25 2015-07-28 Hoffmann La Roche Inibidores de pirrolopirazina quinase.
EP2285378A1 (en) * 2008-03-10 2011-02-23 Sanofi-Aventis Treatment for ocular-related disorders
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
CA2722326A1 (en) * 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010046215A2 (en) * 2008-10-21 2010-04-29 Syngenta Participations Ag Diaza-indole derivatives and their use as fungicides
US8765727B2 (en) * 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
CA2762174C (en) 2009-05-22 2018-02-20 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102471345A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
US8816085B2 (en) 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
EP2338890A1 (en) 2009-12-22 2011-06-29 Bayer CropScience AG 4,7-Diazaindole derivatives and their use as fungicides
WO2011103423A1 (en) * 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
WO2011109932A1 (en) * 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Novel process for the manufacture of 5-halogenated-7-azaindoles
RS60680B1 (sr) 2010-03-10 2020-09-30 Incyte Holdings Corp Piperidin-4-il azetidin derivati kao inhibitori jak1
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
TWI496785B (zh) 2010-05-20 2015-08-21 Hoffmann La Roche 吡咯并吡激酶抑制劑
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
MX357939B (es) 2011-02-18 2018-07-31 Novartis Pharma Ag Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
RU2013154412A (ru) 2011-05-10 2015-06-20 Мерк Шарп И Доум Корп. Аминопиримидины в качестве ингибиторов syc
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
AU2013224420B2 (en) * 2012-02-21 2016-12-15 Merck Patent Gmbh Furopyridine derivatives
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2877467B1 (en) 2012-07-26 2016-11-02 Glaxo Group Limited 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
RS62329B1 (sr) 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
UY35419A (es) * 2013-03-14 2014-10-31 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
BR112015023356A2 (pt) 2013-03-14 2017-07-18 Abbvie Inc inibidores de quinase pirrol[2,3-b]piridina cdk9
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
TWI634111B (zh) * 2013-03-15 2018-09-01 普雷辛肯公司 雜環化合物及其用途
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP6709786B2 (ja) * 2014-12-11 2020-06-17 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
AU2016367147B2 (en) 2015-12-07 2021-04-08 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
JP2020536917A (ja) 2017-10-13 2020-12-17 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節するための化合物の固体形態
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
DK3773593T3 (da) 2018-03-30 2024-05-27 Incyte Corp Behandling af hidradenitis suppurativa under anvendelse af JAK-inhibitorer
EP3897630B1 (en) 2018-12-21 2024-01-10 Celgene Corporation Thienopyridine inhibitors of ripk2
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CR20220280A (es) 2019-11-22 2022-09-02 Incyte Corp Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB966264A (en) 1961-08-31 1964-08-06 Distillers Co Yeast Ltd Production of alkyl pyridines
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (en) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity
US5202108A (en) * 1990-10-12 1993-04-13 Analytical Development Corporation Process for producing ferrate employing beta-ferric oxide
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
EP0763035A4 (en) * 1994-06-09 1997-10-01 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
WO1998006703A1 (en) 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
US5783969A (en) 1996-09-04 1998-07-21 Motorola, Inc. Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array
ES2215242T3 (es) * 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
GB9708235D0 (en) * 1997-04-23 1997-06-11 Ciba Geigy Ag Organic compounds
WO1998047899A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
JP3711238B2 (ja) * 1997-08-05 2005-11-02 ファイザー・プロダクツ・インク 神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
KR100378937B1 (ko) * 1997-10-20 2003-05-09 에프. 호프만-라 로슈 아게 바이사이클릭 키나아제 억제제
JP2002510630A (ja) * 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
CA2326143A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2326139A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1067929A1 (en) 1998-04-02 2001-01-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051595A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002514635A (ja) 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン耐性および高血糖の処置に有用なビフェニルオキソ−酢酸
DE69942801D1 (de) 1998-05-26 2010-11-11 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ439199A3 (cs) * 1998-07-10 2000-07-12 Pfizer Products Inc. 4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y
TR200101395T2 (tr) * 1998-09-18 2001-11-21 Basf Ag. Kinaz engelleyiciler olarak 4-Aminopyrrolopyrimidin'ler
JP4771442B2 (ja) 1998-12-31 2011-09-14 アベンティス・ファーマスーティカルズ・インコーポレイテツド 未保護β−アミノエステル化合物のα−置換
ATE256666T1 (de) 1999-06-04 2004-01-15 Elan Pharma Int Ltd Zusammensetzungen und methoden zur verhinderung des zelltods
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19944051A1 (de) 1999-09-14 2001-03-15 Wilke Heinrich Hewi Gmbh Verriegelungsvorrichtung
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
EP1263759B1 (en) 1999-12-24 2010-09-08 Aventis Pharma Limited Azaindoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
CA2400923A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US6673923B2 (en) * 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2001291013A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds

Also Published As

Publication number Publication date
JP5436507B2 (ja) 2014-03-05
BR0017038A (pt) 2003-01-07
EA200200707A1 (ru) 2003-02-27
AP2006003492A0 (en) 2006-02-28
EP1990343A3 (en) 2008-12-10
BG106836A (bg) 2003-04-30
AP1917A (en) 2008-11-12
KR20020062663A (ko) 2002-07-26
SK9012002A3 (en) 2003-04-01
US7227020B2 (en) 2007-06-05
WO2001047922A3 (en) 2002-01-17
KR20070050103A (ko) 2007-05-14
CN100379734C (zh) 2008-04-09
IL193615A0 (en) 2009-05-04
US6770643B2 (en) 2004-08-03
IL150388A (en) 2010-11-30
EA005212B1 (ru) 2004-12-30
CN1615873A (zh) 2005-05-18
EP1263759B1 (en) 2010-09-08
EP1990343A2 (en) 2008-11-12
PL355819A1 (en) 2004-05-17
KR100910488B1 (ko) 2009-08-04
WO2001047922A2 (en) 2001-07-05
KR100755622B1 (ko) 2007-09-04
HRP20020547B1 (en) 2011-06-30
MXPA02006338A (es) 2002-12-13
CA2699568C (en) 2013-03-12
BG66176B1 (bg) 2011-11-30
SK288019B6 (sk) 2012-11-05
CZ301751B6 (cs) 2010-06-09
OA12514A (en) 2006-05-29
AP2002002516A0 (en) 2002-06-30
HUP0203895A2 (hu) 2003-02-28
CA2699568A1 (en) 2001-07-05
HRP20020547A2 (hr) 2005-10-31
NZ519121A (en) 2004-05-28
AP1587A (en) 2006-03-02
AU2209401A (en) 2001-07-09
CA2395593A1 (en) 2001-07-05
SK287882B6 (sk) 2012-02-03
EE05180B1 (et) 2009-06-15
MA26857A1 (fr) 2004-12-20
PL209572B1 (pl) 2011-09-30
JP2012031181A (ja) 2012-02-16
BG66066B1 (bg) 2011-01-31
CZ20022207A3 (cs) 2002-11-13
CY1110951T1 (el) 2015-06-11
NO20023032D0 (no) 2002-06-21
CN1413213A (zh) 2003-04-23
NO330747B1 (no) 2011-07-04
BG110623A (bg) 2010-07-30
DZ3377A1 (fr) 2001-07-05
HK1050191A1 (en) 2003-06-13
CA2395593C (en) 2011-08-02
EE200200343A (et) 2003-06-16
HUP0203895A3 (en) 2004-09-28
HK1050191B (zh) 2011-04-29
NO20066017L (no) 2002-06-21
NO20023032L (no) 2002-06-21
US20040009983A1 (en) 2004-01-15
EP1263759A2 (en) 2002-12-11
CZ301750B6 (cs) 2010-06-09
EP1990343B1 (en) 2012-04-04
US20040198737A1 (en) 2004-10-07
AU777717B2 (en) 2004-10-28
NO323766B1 (no) 2007-07-02

Similar Documents

Publication Publication Date Title
AP1917A (en) Azaindoles
DE60018571D1 (en) Hernienprothese
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50008011D1 (en) Thixotropierungsmittel
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
DE60027722D1 (en) Aspartyl-protease inhibitoren
PL354600A1 (en) Naphthyridine derivatives
DE50002614D1 (en) Sigma-delta-modulator
DE60007505D1 (en) Propargyletherderivate
DE60011809D1 (en) Oxcarbazepinsuspension
DE50000137D1 (en) Spirofluorenopyrane
DE59909975D1 (en) Testleck
DE10081629D2 (en) Seilzugbefestigung
DE60001313D1 (en) Imidazodiazepinderivate
DE50009469D1 (en) Common-rail-injektor
DE60012950D1 (en) Polyacetalharzzusammensetzung
HUP0200274A2 (en) Fitting
DE50010757D1 (en) Stilbenaufheller
DE50012999D1 (en) Stirnwandisolation
DE60026282D1 (en) Photovervielfacherröhre
DE50008218D1 (en) Common-rail-injektor
EP1170018A4 (en) COMPLEX LINKED BY A LIGAND
DE60012212D1 (en) Orthotopisches totalkunstherz